Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 3/5 criteria met.
- ✅ Price trend passed
- ✅ Growth passed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: 28.79%
Price change 2019 → 2020: 84.71%
Price change 2020 → 2021: -11.31%
Price change 2021 → 2022: -34.29%
Price change 2022 → 2023: 80.05%
Price change 2023 → 2024: 48.41%
Price change 2024 → 2025: -61.84%
Price change 2025 → 2026: 16.72%
Price change 2026 (year to date): 20.27%
Financial growth
Revenue CAGR (8 years): 23.26%
Earnings CAGR (8 years): 10.28%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.06
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 74.56
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 29.51% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="XVIVO.ST" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Xvivo Perfusion AB (publ) | 48.0 | 0.06 | +36.1 % | 🔒 |
| 4D Molecular Therapeutics, Inc. | – | 0.04 | +40.0 % | – |
| Lumibird S.A. | 38.1 | 0.71 | +9.8 % | – |
| National Research Corporation | 31.5 | 5.65 | +5.3 % | – |
| Valneva SE | – | 1.95 | +22.4 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Xvivo Perfusion AB (publ) over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 17.9 m | -4.3 m | -24.3 % | n/a |
| 2021 | 25.7 m | 809,300 | 3.1 % | +43.7 % |
| 2022 | 41.2 m | 1.8 m | 4.4 % | +60.7 % |
| 2023 | 59.3 m | 9.1 m | 15.4 % | +43.9 % |
| 2024 | 81.6 m | 17.1 m | 20.9 % | +37.6 % |
| 2025 | 80.6 m | 2.5 m | 3.1 % | -1.2 % |
Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Xvivo Perfusion AB (publ) over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 399 m | 247 m | 546 m | 416 m | 292 m |
| Total Debt | 5.7 m | 10.0 m | 31.4 m | 34.0 m | 125 m |
| Net Debt | -393 m | -237 m | -514 m | -381 m | -167 m |
| Equity | 1.3 bn | 1.4 bn | 1.9 bn | 2.2 bn | 2.1 bn |
| Total assets | 1.5 bn | 1.7 bn | 2.2 bn | 2.4 bn | 2.4 bn |
| Operating cash flow | -12.1 m | 27.9 m | 46.3 m | 111 m | 101 m |
| Investments (capex) | 94.1 m | 131 m | 43.0 m | 193 m | 101 m |
| Free cash-flow | -106 m | -103 m | -97.6 m | -81.9 m | -152 m |
| Share buybacks | 0 | 368,000 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in SEK, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 18/11/2026.
Valuation and competitors
Xvivo Perfusion AB (publ) compared with its sector on the same exchange and with its main competitors.
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
Xvivo Perfusion AB (publ): dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Earnings releases
| Date | Published EPS | Expected EPS | Surprise |
|---|---|---|---|
| 22/10/2026 | 1.39 | 0.64 | +116.2 % |
| 14/07/2026 | 0.52 | 0.75 | -31.0 % |
| 24/04/2026 | 1.15 | 0.94 | +21.8 % |
| 27/01/2026 | 1.05 | 0.68 | +53.5 % |
| 23/10/2025 | 0.26 | 0.44 | -41.2 % |
| 11/07/2025 | 0.05 | 0.62 | -91.9 % |
Factual data: ex-dividend history and earnings calendar, as of 18/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Xvivo Perfusion AB (publ).
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Xvivo Perfusion AB (publ)
What is the Xvivo Perfusion AB (publ) share price?
Latest recorded price: 206.00 SEK on 13/11/2026, for a market cap of 644 m USD.
What is the revenue of Xvivo Perfusion AB (publ)?
80.6 m USD for fiscal year 2025, with net income of 2.5 m USD (net margin 3.1 %).
What is the P/E ratio of Xvivo Perfusion AB (publ)?
Trailing 12-month P/E of 50.1.
Is Xvivo Perfusion AB (publ) stock eligible for the French PEA?
Likely: the company is headquartered in the European Union or the European Economic Area (ISIN SE0004840718) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.
How many employees does Xvivo Perfusion AB (publ) have?
193 full-time employees according to the latest published profile.
Who runs Xvivo Perfusion AB (publ)?
Christoffer Rosenblad is the company's chief executive.